Watchlist 2020: CBD Restrictions, FTC Scrutiny and Problematic Comp Plans
January 1, 2020
2020 to see issues stay at forefront; comp plan changes most urgent
By Teresa Craighead
What’s on the horizon for direct sellers at the beginning of 2020? Three issues that appear to stand above the rest are the growing regulations around the exploding CBD market, the direction and manner of Federal Trade Commission (FTC) scrutiny and where it will next focus, and the most problematic elements of complicated compensation plans.
CBD Regulations
The Federal Drug Administration (FDA) is struggling to develop regulations and guidance amdist the exploding demand for products containing cannabidiol (CBD).
Please log in (or register) to continue viewing this content.
